ES2179273T3 - N-bencil-2-fenilindolas como agentes estrogenicos. - Google Patents

N-bencil-2-fenilindolas como agentes estrogenicos.

Info

Publication number
ES2179273T3
ES2179273T3 ES97302577T ES97302577T ES2179273T3 ES 2179273 T3 ES2179273 T3 ES 2179273T3 ES 97302577 T ES97302577 T ES 97302577T ES 97302577 T ES97302577 T ES 97302577T ES 2179273 T3 ES2179273 T3 ES 2179273T3
Authority
ES
Spain
Prior art keywords
phenylindols
bencil
compounds
estrogenic agents
estrogenic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97302577T
Other languages
English (en)
Inventor
Chris P Miller
Bach D Tran
Michael D Collini
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
Wyeth LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth LLC filed Critical Wyeth LLC
Application granted granted Critical
Publication of ES2179273T3 publication Critical patent/ES2179273T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12—Radicals substituted by oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Indole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A NUEVOS COMPUESTOS 3 [4 (2 UEVOS COMPUESTOS 2 1 STROGENICOS Y COMO COMPUESTOS FARMACEUTICOS Y ASI COMO A METODOS DE TRATAMIENTO UTILIZANDO ESTOS COMPUESTOS CON LAS FORMULAS GENERALES SIGUIENTES: DONDE Z SE SELECCIONA DE O UB,2}){SUB,N}
ES97302577T 1996-04-19 1997-04-15 N-bencil-2-fenilindolas como agentes estrogenicos. Expired - Lifetime ES2179273T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63397696A 1996-04-19 1996-04-19
US63397296A 1996-04-19 1996-04-19

Publications (1)

Publication Number Publication Date
ES2179273T3 true ES2179273T3 (es) 2003-01-16

Family

ID=27092024

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97302577T Expired - Lifetime ES2179273T3 (es) 1996-04-19 1997-04-15 N-bencil-2-fenilindolas como agentes estrogenicos.

Country Status (23)

Country Link
EP (1) EP0802184B1 (es)
JP (1) JPH1036347A (es)
KR (1) KR970069986A (es)
CN (1) CN1103756C (es)
AR (1) AR006705A1 (es)
AT (1) ATE219485T1 (es)
AU (1) AU718888B2 (es)
BR (1) BR9701879A (es)
CO (1) CO4950540A1 (es)
CZ (1) CZ293065B6 (es)
DE (1) DE69713441T2 (es)
DK (1) DK0802184T3 (es)
EA (1) EA000815B1 (es)
ES (1) ES2179273T3 (es)
HU (1) HUP9700779A1 (es)
ID (1) ID16618A (es)
IL (1) IL120699A0 (es)
NO (1) NO308214B1 (es)
NZ (1) NZ314595A (es)
PT (1) PT802184E (es)
SK (1) SK282765B6 (es)
TW (1) TW397821B (es)
UA (1) UA47413C2 (es)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6069153A (en) * 1998-05-12 2000-05-30 American Home Products Corporation Indenoindoles and benzocarbazoles as estrogenic agents
CN1173973C (zh) * 1998-05-12 2004-11-03 惠氏公司 苯并咔唑和茚并吲哚衍生的雌激素药
EE04262B1 (et) * 1998-05-15 2004-04-15 American Home Products Corporation Östrogeeni ja 2-fenüül-1-[4-(2-aminoetoksü)bensüül]indooli ühendit sisaldav farmatseutiline kompositsioon ja produkt
JP2002515484A (ja) * 1998-05-15 2002-05-28 アメリカン・ホーム・プロダクツ・コーポレイション ２−フェニルインドール化合物およびエストロゲン製剤からなる組成物
US6479535B1 (en) 1998-05-15 2002-11-12 Wyeth 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole and estrogen formulations
AU2004200099B2 (en) * 1998-06-11 2006-11-02 Endorecherche, Inc. Medical Uses of A Selective Estrogen Receptor Modulator in Combination with Sex Steroid Precursors
US7005428B1 (en) 1998-06-11 2006-02-28 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
US6465445B1 (en) 1998-06-11 2002-10-15 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
EP1212335B1 (en) * 1999-09-13 2006-01-18 Wyeth Glucopyranosides conjugates of 2-(4-hydroxy-phenyl)-1- 4-(2-amin-1-yl-ethoxy)-benzyl]-1h-indol-5-ols
US6455568B2 (en) 2000-07-06 2002-09-24 Wyeth Combination therapy for inhibiting sphincter incontinence
WO2002003991A2 (en) * 2000-07-06 2002-01-17 Wyeth Use of substituted indole compounds for increasing nitric oxide synthase activity
AR029538A1 (es) 2000-07-06 2003-07-02 Wyeth Corp Composiciones farmaceuticas de agentes estrogenicos
JP2004502729A (ja) * 2000-07-06 2004-01-29 ワイス Ｓｓｒｉおよびエストロゲン剤の組み合わせ
AR029539A1 (es) 2000-07-06 2003-07-02 Wyeth Corp Combinaciones de estatinas y agentes estrogenicos
US6369051B1 (en) 2000-07-06 2002-04-09 American Home Products Corporation Combinations of SSRI and estrogenic agents
US6376486B1 (en) 2000-07-06 2002-04-23 American Home Products Corporation Methods of inhibiting sphincter incontinence
AR030064A1 (es) * 2000-07-06 2003-08-13 Wyeth Corp Metodos para inhibir los efectos uterotroficos de los agentes estrogenicos
AU2001271781A1 (en) * 2000-07-06 2002-01-21 Wyeth Use of substituted indole compounds for treating sphincter incontinence
WO2002003992A2 (en) * 2000-07-06 2002-01-17 Wyeth Use of substituted indole compounds for treating prosthesis-related bone degeneration
AU2001273144A1 (en) * 2000-07-06 2002-01-21 Wyeth Use of substituted indole compounds for treating neuropeptide y-related conditions
WO2002003986A2 (en) * 2000-07-06 2002-01-17 Wyeth Use of substituted indole compounds for treating breast disorders
EP1656938A1 (en) 2000-07-06 2006-05-17 Wyeth Combinations of SSRI and estrogenic agents
WO2002003990A2 (en) * 2000-07-06 2002-01-17 Wyeth Use of substituted insole compounds for treating excessive intraocular pressure
EP1491524B1 (en) * 2000-08-24 2009-02-18 University of Tennessee Research Foundation Selective androgen receptor modulators and methods of use thereof
ATE321754T1 (de) 2001-05-22 2006-04-15 Lilly Co Eli 2-substituierte 1,2,3,4-tetrahydrochinoline und derivate davon, zusammensetzungen und verfahren
JP2004531559A (ja) 2001-05-22 2004-10-14 イーライ・リリー・アンド・カンパニー エストロゲン欠乏または内因性エストロゲンに対する異常な生理反応に関連する疾患を抑制するためのテトラヒドロキノリン誘導体
EP1732890A1 (en) 2004-04-07 2006-12-20 Wyeth Crystalline polymorph of a bazedoxifene acetate
KR20070004815A (ko) 2004-04-07 2007-01-09 와이어쓰 바제독시펜 아세테이트의 결정질 다형체
CA2561004A1 (en) 2004-04-08 2005-10-27 Wyeth Bazedoxifene ascorbate as selective estrogen receptor modulator
JP2008506702A (ja) 2004-07-14 2008-03-06 ピーティーシー セラピューティクス，インコーポレーテッド Ｃ型肝炎を治療するための方法
US7772271B2 (en) 2004-07-14 2010-08-10 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7781478B2 (en) 2004-07-14 2010-08-24 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7868037B2 (en) 2004-07-14 2011-01-11 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7645881B2 (en) 2004-07-22 2010-01-12 Ptc Therapeutics, Inc. Methods for treating hepatitis C
MX2007004830A (es) 2004-10-20 2007-10-04 Endorech Inc Precursores esteroides sexuales solos o en combinacion con un modulador receptor de estrogeno selectivo y/o con estrogenos y/o con un inhibidor de fosfodiesterasa gmpc de tipo 5 para la prevencion y tratamiento de resequedad vaginal y disfuncion sexu
US7553861B2 (en) 2005-04-22 2009-06-30 Alantos Pharmaceuticals Holding, Inc. Dipeptidyl peptidase-IV inhibitors
US8268806B2 (en) 2007-08-10 2012-09-18 Endorecherche, Inc. Pharmaceutical compositions
US20100317635A1 (en) 2009-06-16 2010-12-16 Endorecherche, Inc. Treatment of hot flushes, vasomotor symptoms, and night sweats with sex steroid precursors in combination with selective estrogen receptor modulators
KR20200144591A (ko) 2010-06-16 2020-12-29 앙도르쉐르슈 인코포레이티드 에스트로겐-관련 질병의 치료 또는 예방 방법
US9744177B2 (en) 2014-03-10 2017-08-29 Endorecherche, Inc. Treatment of male androgen deficiency symptoms or diseases with sex steroid precursor combined with SERM
PE20181083A1 (es) 2015-05-29 2018-07-05 Eisai Randd Man Co Ltd Compuestos alqueno tetrasustituidos y su uso
RS62133B1 (sr) 2015-10-01 2021-08-31 Olema Pharmaceuticals Inc Tetrahidro-1h-pirido[3,4-b]indol antiestrogeni lekovi
RU2747802C2 (ru) 2015-12-09 2021-05-14 Зе Боард Оф Трастис Оф Зе Юниверсити Оф Иллинойс Бензотиофеновые селективные блокаторы эстрогеновых рецепторов
KR102111792B1 (ko) * 2016-03-25 2020-05-18 뤄신 바이오테크놀러지 (상하이) 컴퍼니 리미티드 에스트로겐 수용체 하향 조절제로서의 치환된 인돌 화합물
EP4491236A3 (en) 2016-05-10 2025-04-02 C4 Therapeutics, Inc. Heterocyclic degronimers for target protein degradation
EP4483875A3 (en) 2016-05-10 2025-04-02 C4 Therapeutics, Inc. Spirocyclic degronimers for target protein degradation
EP3455219A4 (en) 2016-05-10 2019-12-18 C4 Therapeutics, Inc. AMINE-RELATED C3-GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION
EP3455218A4 (en) 2016-05-10 2019-12-18 C4 Therapeutics, Inc. C3 CARBON-BASED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION
MX2019000200A (es) 2016-07-01 2019-09-26 G1 Therapeutics Inc Agentes antiproliferativos basados en pirimidina.
WO2018081168A2 (en) 2016-10-24 2018-05-03 The Board Of Trustees Of The University Of Illinois Benzothiophene-based selective mixed estrogen receptor downregulators
CN109790141B (zh) 2016-11-28 2021-06-11 卫材 R&D 管理有限公司 吲唑衍生物的盐及其晶体
MX2019008158A (es) 2017-01-06 2019-12-09 G1 Therapeutics Inc Terapia de combinacion para el tratamiento del cancer.
US10208011B2 (en) 2017-02-10 2019-02-19 G1 Therapeutics, Inc. Benzothiophene estrogen receptor modulators
WO2018237026A1 (en) 2017-06-20 2018-12-27 C4 Therapeutics, Inc. N/o-linked degrons and degronimers for protein degradation
NZ759691A (en) 2017-06-29 2023-05-26 G1 Therapeutics Inc Morphic forms of git38 and methods of manufacture thereof
EP3897631A4 (en) 2018-12-20 2022-11-23 C4 Therapeutics, Inc. TARGETED PROTEIN DEGRADATION
JP7616794B2 (ja) 2019-07-07 2025-01-17 オレマ ファーマシューティカルズ インク． エストロゲン受容体アンタゴニストのレジメン
MX2022000520A (es) 2019-07-22 2022-02-10 Radius Pharmaceuticals Inc Compuestos moduladores del receptor de estrogeno.
WO2021127561A1 (en) 2019-12-20 2021-06-24 C4 Therapeutics, Inc. Isoindolinone and indazole compounds for the degradation of egfr
CN119823124A (zh) 2020-03-05 2025-04-15 C4医药公司 用于brd9的靶向降解的化合物
CN116490186B (zh) 2020-08-05 2025-10-31 C4医药公司 用于ret的靶向降解的化合物
WO2024030968A1 (en) 2022-08-03 2024-02-08 Brystol-Myers Squibb Company Compounds for modulating ret protein
KR20250116017A (ko) 2022-11-04 2025-07-31 브리스톨-마이어스 스큅 컴퍼니 Ret-ldd 단백질 억제제
EP4611901A1 (en) 2022-11-04 2025-09-10 Bristol-Myers Squibb Company Ret-ldd protein degraders
WO2025006753A2 (en) 2023-06-30 2025-01-02 Merck Patent Gmbh Heterobifunctional compounds for the degradation of kras protein

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3232968A1 (de) * 1981-09-10 1983-06-09 Degussa Ag, 6000 Frankfurt Neue 2-(hydroxy-phenyl)-indole und verfahren zu deren herstellung
DE3821148A1 (de) * 1988-06-23 1989-12-28 Erwin Von Dr Angerer Aminoalkylindole, verfahren zu deren herstellung und diese enthaltende pharmazeutische praeparate
US5395842A (en) * 1988-10-31 1995-03-07 Endorecherche Inc. Anti-estrogenic compounds and compositions
GB9108811D0 (en) * 1991-04-24 1991-06-12 Erba Carlo Spa N-imidazolyl derivatives of substituted indole
RU2061694C1 (ru) * 1991-09-11 1996-06-10 Е.Р.Сквибб энд Санз, Инк., Производные индола
FR2708605A1 (fr) * 1993-07-30 1995-02-10 Sanofi Sa Dérivés du N-sulfonylindol-2-one, leur préparation, les compositions pharmaceutiques en contenant.
CA2135160A1 (en) * 1992-05-08 1993-11-25 Masatoshi Inai Indole derivative
GB9326332D0 (en) * 1993-12-23 1994-02-23 Karo Bio Indole derivatives
KR100362864B1 (ko) * 1994-02-22 2003-04-16 메렐 파마슈티칼스 인크. 에스트로겐관련신생물및질환의치료에유용한신규인돌유도체
DE4426625A1 (de) * 1994-07-27 1996-03-14 Schering Ag 2-Phenylindole, Verfahren zu deren Herstellung, diese enthaltende pharmazeutische Präparate sowie deren Verwendung zur Herstellung von Arzneimitteln

Also Published As

Publication number Publication date
EP0802184A1 (en) 1997-10-22
NO308214B1 (no) 2000-08-14
TW397821B (en) 2000-07-11
UA47413C2 (uk) 2002-07-15
EA199700043A1 (ru) 1997-12-30
HUP9700779A1 (hu) 1999-09-28
NO971814L (no) 1997-10-20
CN1103756C (zh) 2003-03-26
AR006705A1 (es) 1999-09-08
DE69713441D1 (de) 2002-07-25
JPH1036347A (ja) 1998-02-10
DK0802184T3 (da) 2002-09-16
EA000815B1 (ru) 2000-04-24
CO4950540A1 (es) 2000-09-01
DE69713441T2 (de) 2002-11-07
HK1002862A1 (en) 1998-09-25
CN1168373A (zh) 1997-12-24
CZ293065B6 (cs) 2004-02-18
ATE219485T1 (de) 2002-07-15
PT802184E (pt) 2002-09-30
ID16618A (id) 1997-10-23
CZ117697A3 (en) 1997-12-17
AU1892197A (en) 1997-10-23
KR970069986A (ko) 1997-11-07
SK282765B6 (sk) 2002-12-03
IL120699A0 (en) 1997-08-14
BR9701879A (pt) 1998-09-29
AU718888B2 (en) 2000-04-20
NZ314595A (en) 2000-04-28
NO971814D0 (no) 1997-04-18
HU9700779D0 (en) 1997-06-30
EP0802184B1 (en) 2002-06-19
SK47197A3 (en) 1997-11-05

Similar Documents

Publication Publication Date Title
ES2179273T3 (es) N-bencil-2-fenilindolas como agentes estrogenicos.
ES2162198T3 (es) Agentes estrogenos.
ES2194314T3 (es) Derivados de benzopirano sustituidos para el tratamiento de inflamaciones.
BG99261A (en) Steroid glycosides for the treatment of hyperchlesterolemia
GT199900067A (es) Nuevas 4-fenilpiperidinas para el tratamiento dedermatosis prurìtica.
ES2190803T3 (es) Iminas ciclicas como pesticidas.
ES2195970T3 (es) L-ribavirina y usos de la misma.
CR9879A (es) Moduladores de ccr5 (divisional de la solicitud n° 6392)
DE59709414D1 (de) Oxyiminopregnancarbolactone
ES2145915T3 (es) Derivados estereoquimicos de la wortmannina.
ES2158327T3 (es) Derivados de benzo(g)quinolina.
MD1745B2 (en) 4,5-dimethyl-N-2-propenyl-2-(trimethylsilyl)-3-thiophencarboxamide, fungicidal composition on base thereof and method of plants diseases control
ES2188984T3 (es) Procedimiento de enriquecimiento en r de epimeros de derivados de 16,17-acetales de derivados de 21-aciloxi-pregnano-1,4-dieno-11-beta, 16alfa-triol-3,20-dionas.
IT1285770B1 (it) Composti corticoidei
ES2193241T3 (es) Nuevas n-2-oxo2.3.4.5-tetrajodrp-1h-1,5-benzodiazepin-3-il)-3-amidas.
ATE202483T1 (de) Immuntolerante prothrombinkomplex-präparation
ES2142512T3 (es) Nuevas substancias odoriferas.
ES2151168T3 (es) N-(2,4-dioxo-2,3,4,5-tetrahidro-1h-1,5-benzodiazepin-3-il)-3-amidas.
SE9801494D0 (sv) Novel use
DE60006825D1 (de) Serotonerge benzofurane
ES2159054T3 (es) Compuestos di-terc-butil-fenolicos que contienen azufre utiles como agentes antiinflamatorios.
BR0012921A (pt) Compostos calcilìticos
DE69805988D1 (de) Herstellung von 1,3-diaminopentan durch hydrierung von 3-aminopentanitril
ATE160573T1 (de) 1,3.5 (10) - estratriene derivate mit oraler wirkung
ES2128112T3 (es) Nuevas composiciones herbicidas.